Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 29, 2007

Equity Firm to Procure Axcan for $1.3B

  • Axcan Pharma, which focuses on treatments for gastrointestinal diseases, will be acquired by TPG Capital, an investment company. The all-cash transaction is worth approximately $1.3 billion.

    TPG Capital and its affiliates will purchase all of Axcan’s common shares for $23.35 per share. This represents a 28% premium over the company’s closing price on November 28. Axcan opened trading today at $22.67.

    The transaction will be financed through a combination of equity contributed by TPG Capital and its affiliates and debt financing that has been committed by Bank of America and HSBC.

    Axcan anticipates that the transaction will be completed in the first calendar quarter of 2008. The firm’s stock will then be delisted. Headquarters will remain in Quebec, Canada.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »